apeiron biolog ag privat clinic stage biotechnolog compani focus
develop immunolog cancer treatment lead clinic asset
person cellular therapi base target cbl-b immun cell checkpoint
neg regul cell activ compani plan begin phase ii studi
patient pancreat cancer first half apeiron approv
product candid dinutuximab beta chimer antibodi
gangliosid antigen may receiv market approv eu
brand name qarziba treatment high-risk pediatr neuroblastoma rare form
cancer compris roughli childhood tumor apeiron out-licens
global commerci right eusa pharma privat exchang
up-front payment regulatori mileston royalti fulli human
monoclon antibodi genet fuse human activ shown
phase melanoma studi use intraven therapi phase studi plan begin
evalu intratumor melanoma
point discuss
person cellular therapi base cbl-b checkpoint immun cell person cellular
therapi develop treat cancer base intracellular checkpoint cbl-b immun cell therapi involv
remov peripher blood mononuclear cell pbmc patient silenc cbl-b ex vivo via sirna engin cell
reinfus patient take hour bedsid cbl-b intracellular checkpoint immun cell
neg regul cell activ inhibit activ cbl-b apeiron intend restor improv anti-canc immun
preclin cbl-b deplet lead enhanc immun respons cbl-b knock-out lead tumor reject
evalu dose-escal phase studi use single-dos patient advanc solid tumor
progress diseas preliminari result show patient experienc stabl diseas pancreat cancer colon cancer
compassion use program also show activ pancreat cancer apeiron current evalu phase ib
studi repeat administr multipl tumor type plan begin phase ii studi pancreat cancer first
half compani note futur approach util ex vivo silenc immun cell may target addit immun
relat protein enhanc immun respons
target antibodi approv eu high-risk neuroblastoma dinutuximab beta
intraven iv administ chimer antibodi gangliosid antigen may receiv
market approv eu brand name qarziba patient month age older high-risk pediatr
neuroblastoma rare form cancer compris roughli childhood tumor approv author except
circumst mean post market surveil use patient registri mandat
apeiron out-licens global right eusa pharma privat septemb term agreement
apeiron receiv undisclos up-front payment elig regulatori mileston payment follow market author
select territori royalti product sale apeiron expect bla submit fda eusa second
quarter grant fda track design orphan drug design us eu given
neuroblastoma primarili affect pediatr patient potenti receiv pediatr diseas prioriti review
voucher fda approv voucher sold compani price typic surpass million
reach roughli million
analyst certif disclosur pleas see page
target immunotherapi posit cancer apeiron in-licens merck kgaa
asset fulli human monoclon antibodi genet fuse human activ
agent observ phase ii studi use iv relapsed/refractori neuroblastoma overal respons rate
treatment around patient low tumor burden melanoma iv monotherapi evalu phase ii studi
patient late stage diseas one patient experienc partial respons stabl diseas base result preclin
studi use intratumor treatment investigator-l phase studi evalu intratumor melanoma plan
begin first half initi data expect apeiron also intend initi clinic studi pediatr
cancer use intratumor second half
preclin develop call apn develop collabor sanofi nyse
sni evotec evt term agreement sanofi fund research apeiron evotec
two compani could receiv million million combin pre-clin clinic regulatori commerci
mileston addit royalti net sale commerci
apeiron also out-licens glaxosmithklin nyse gsk up-front payment million million
million million total mileston payment plu royalti net product sale commerci
recombin form human angiotensin convert enzym assess phase ii studi acut lung
injuri ali acut respiratori distress syndrom ard also pursu pulmonari arteri hypertens
file us approv high-risk neuroblastoma eusa
phase ib data advanc solid tumor
begin phase ii studi pancreat cancer
begin phase studi intratumor melanoma
establish preclin proof-of-concept
begin phase i/ii studi pediatr cancer
initi data phase studi intratumor melanoma
sanofi may progress lead drug candid clinic
tabl content
small interf rna sirna method gene silenc
clinic trial discuss
clinic trial discuss
phase studi compar without follow first line therapi
preclin studi intratumor
clinic trial discuss
phase ii studi iv advanc melanoma
investig sponsor studi iv resect recurr melanoma
risk invest
apeiron biolog ag privat biotechnolog compani focus develop immunolog cancer
treatment compani lead clinic candid person cellular therapi base target cbl-
 cbl-b intracellular checkpoint immun cell neg regul cell activ inhibit
activ cbl-b via ex vivo silenc cbl-b apeiron intend restor improv anti-canc immun
preclin cbl-b deplet lead enhanc immun respons cbl-b knockout lead tumor
evalu dose-escal phase studi use single-dos treatment patient
advanc solid tumor progress diseas preliminari result show patient experienc
stabl diseas pancreat cancer colon cancer compassion use program also show activ
pancreat cancer apeiron current evalu treatment phase ib studi repeat use multipl
tumor type plan begin phase ii studi pancreat cancer first half futur
treatment may util ex vivo silenc addit immun checkpoint enhanc immun respons
compani full development pipelin shown figur
dinutuximab beta chimer antibodi gangliosid antigen develop
neuroblastoma tumor type may receiv market approv eu
brand name qarziba treatment high-risk pediatr neuroblastoma rare form cancer compris
loeser et al spontan tumor reject cbl-b-defici cell journal experiment medicin
roughli childhood tumor apeiron out-licens global commerci right eusa
pharma privat exchang undisclos up-front payment elig regulatori mileston
payment follow market author select territori royalti product sale notabl
approv immunotherapi neuroblastoma eu apeiron expect regulatori file us
submit eusa second quarter clinic studi also conduct japan support
approv territori
apeiron in-licens merck kgaa asset fulli human
monoclon antibodi genet fuse human proof-of-concept establish phase ii studi
use iv relapsed/refractori neuroblastoma overal respons rate treatment around
patient low tumor burden melanoma iv monotherapi data report patient
late stage diseas enrol phase ii studi one patient experienc partial respons stabl diseas
short half-lif may limit activ intraven treatment base
preclin result use intratumor therapi investigator-l phase studi plan begin
first half evalu intratumor melanoma initi data trial expect
apeiron also intend initi clinic studi use intratumor pediatr cancer
second half
candid includ small molecul checkpoint inhibitor preclin develop call apn
develop collabor sanofi nyse sni evotec
evt term agreement sanofi fund research apeiron evotec two
compani opportun receiv million million combin preclin clinic
regulatori commerci mileston addit royalti net sale commerci
addit recombin form human angiotensin convert enzym
complet phase ii studi acut lung injuri ali acut respiratori distress syndrom ard
pursu pulmonari arteri hypertens outlicens glaxosmithklin nyse gsk follow
phase studi up-front payment million million million million total
mileston payment plu royalti net product sale commerci
person cellular therapi develop treat cancer base intracellular checkpoint cbl-
 immun cell therapi remov peripher blood mononuclear cell pbmc patient silenc
cbl-b ex vivo via sirna engin cell reinfus patient take hour
bedsid complet process cbl-b intracellular checkpoint immun cell neg regul
cell activ inhibit activ cbl-b apeiron intend restor improv anti-canc immun
preclin cbl-b deplet lead enhanc immun respons cbl-b knock lead tumor
evalu dose-escal phase studi use single-dos patient advanc solid
tumor progress diseas preliminari result show patient experienc stabl diseas
pancreat cancer colon cancer compassion use program also show activ pancreat cancer
loeser et al spontan tumor reject cbl-b-defici cell journal experiment medicin
apeiron current evalu treatment phase ib studi repeat administr multipl tumor
type plan begin phase ii studi pancreat cancer first half compani
note futur approach util ex vivo silenc immun cell may target addit immun relat
protein enhanc immun respons
mechan action individu cellular immunotherapi target ubiquitin protein
ligas cbl-b immun cell ex vivo silenc sirna downregul specif mrna transcript interest
case cbl-b function result gene silenc multipl rna interfer rnai pathway
treatment process depict figur shown step patient hospit set undergo leukapheresi
extract blood contain pbmc pbmc isol use centrifug step
appropri sirna electropor pbmc silenc cbl-b gene step final transfect cell
reinject intraven patient step overal process take less day plan occur
everi week tumor progress notabl apeiron on-going collabor miltenyi privat
develop close system machin handl modifi pbmc cell
inject patient
sirna electropor pbmc
silenc cbl-b gene
pbmc isol centrifug
process take less one day done hospit
potenti compat car-t dc vaccin til therapi
note pbmc peripher blood mononuclear cell t-cell b-cell nk-cell monocyt
background cbl-b cbl-b protein member mammalian famili cbl ubiquitin ligas
intracellular checkpoint immun cell function neg regul cell activ express
cell lead down-modul cell receptor prevent activ via antigen present
experi mice shown cbl-b deplet lead enhanc immun respons cbl-b knock
lead tumor importantli cbl-b -/- cell resist regulatori cell suppress
demonstr enhanc activ tumor infiltr may synerg well checkpoint inhibitor
merck nyse keytruda pembrolizumab bristol-my squibb nyse opdivo nivolumab
addit sirna
loeser et al spontan tumor reject cbl-b-defici cell journal experiment medicin
cbl-b intracellular checkpoint
ligas cbl-b neg gatekeep immun
cbl-b knock mice reject tumor loeser et al
figur depict pathway cbl-b downregul mani involv type interferon ifn respons
pathway promis immunotherapi target investig clinic studi pathway help
regul innat adapt immun direct indirect mechan affect macrophag monocyt
natur killer cell dendrit cell cell notabl intratumor express type ifn ifn-
stimul gene correl favor outcom sever cancer type mous studi shown
type ifn signal play import role initi cell prime lead increas level
cbl-b central limit immun cell activ
anti-tumor immun respons limit cbl-b
figur function cbl-b
small interf rna sirna method gene silenc nearli twenti year ago ribonucl acid
interfer rnai technolog discov upon realiz double-strand rna dsrna could
silenc gene express fundament level rnai allow sequence-specif target
cleavag mrna function result reduct translat target sequenc extent
gene silenc process requir introduct dsrna cytoplasm target cell
subsequ cleav small interf rna sirna enzym call dicer introduct sirna
directli bypass dicer sirna load rna-induc silenc complex risc
protein call argonaut unwind dsrna cleav sens passeng strand
fuert et al type ifn respons innat immun sens cancer trend immunol
fuert et al host type ifn signal requir antitumor cell respons dendrit
whitehead et al knock barrier advanc sirna deliveri natur review
bernstein et al role bident ribonucleas initi step rna interfer natur
rand et al biochem identif argonaut sole protein requir rna-induc silenc
complex activ proceed nation academi scienc
point risc exclus hold antisens rna strand activ bind cleav endogen
risc-sirna activ complex recycl mani time propag genet silenc target sequenc
process depict figur note administ therapeut sirna eventu
dilut cell divis degrad within cell thu requir recur drug administr
experi sinc perform assess applic sirna short sequenc double-
strand rna approxim nucleotid length use mrna sequenc specif knockdown
data one preliminari gene silenc experi sirna technolog perform mous
model autoimmun hepat indic success prevent diseas treat anim serv
catalyst develop rnai therapi applic technolog broad nearli gene
bodi silenc via rnai variou approach sinc assess sever therapeut area
includ viral infect hepat cardiovascular diseas sever cancer among
figur mechan rna interfer
one primari hurdl develop sirna technolog deliveri cytoplasm rna-
induc silenc complex risc found requir pass cellular endosom
amer et al molecular basi target rna recognit cleavag human risc cell
problemat sirna due suscept enzymat degrad endosom
size kda neg charg leav incap cross membran thu method cell
deliveri effect non-tox critic hurdl sirna technolog apeiron technolog aim
circumv hurdl appli sirna ex vivo electropor therebi provid treatment directli
cell interest promot membran penetr rather reli system traffick
sirna platform provid opportun addit target consid broad potenti sirna
technolog apeiron plan expand target select includ cbl-b exampl
compani use gene edit technolog delet chimer antigen receptor
cell void tumor induc immunosuppress inhibitor merck keytruda bristol-my
squibb opdivo work block key immun checkpoint call often prevent cell
recogn attack tumor cell class therapeut becom import treatment option
patient sever form cancer apeiron ex vivo sirna platform immun cell could use
car-t cell tumor infiltr lymphocyt til therapi note compet
edit work upstream point intervent sirna compani greatest potenti could
target multipl pbmc gene interest ex vivo follow-on sirna product enhanc immun cell activ
compani mention possibl target includ follow-on product
phosphatas intracellular enzym play role suppress immun cell activ function
addit therapeut opportun could includ combin approach therapeut vaccin antibodi
cbl-b shown play role adapt innat immun system enhanc anti-tumor
effect immun cell mice lack cbl-b shown effect reject highli aggress tumor
suggest therapeut modal reduc express may anti-canc sever studi
perform investig consequ cbl-b deplet use small interf rna sirna
discuss figur activ human cell transfect sirna direct cbl-b mrna result
higher level ifn-g cell prolifer compar control ifn-g product
associ anti-tumor activ
wittrup et al knock diseas progress report sirna therapeut natur review genet
loeser et al spontan tumor reject cbl-b defici cell pp
chiang et al ablat cbl-b provid protect transplant spontan tumor clin invest
figur highlight preclin studi
vitro result human nk cell
anti-tumor respons cbl-b defici mice
cbl-b defici mice protect variou
cbl-b defici cell specif tumor
transfer cbl-b defici cell
cbl-b defici nk cell hyper-react
display enhanc cytotox tumor
cbl-b defici nk cell resist
cbl-b silenc human cell reproduc
phenotyp cbl-b defici murin cell
cbl-b silenc enhanc product anti-
tumor cytokin ifn- cell receptor
cbl-b silenc cell prolifer
respons even presenc tgf-b
tcr stimul cbl-b silenc cell result
higher express surfac activ
marker key cell-cel interact
cbl-b silenc nk hyper-react
stimul cytokin tumor cell
cbl-b sirna proof-of-concept preclin studi order confirm vitro observ apeiron harvest
cell wildtyp mice transient downregul cbl-b express use sirna toward cbl-b similar
experi perform human cell manipul cell mix ova-vaccin dendrit
cell dc enhanc anti-tumor cell respons wildtyp mice receiv melanoma cell xenograft
adopt transfect genet manipul immun cell subsequ monitor tumor
growth figur show adopt cell transfer act cbl-b deplet cell green day
limit tumor growth longer period time compar control red blue line untreat mice
black tumor growth monitor function tumor volum y-axi time x-axi inset top
right corner figur immunoblot show downregul cbl-b protein right lane cbl-b sirna
transfect cell compar control left lane togeth studi help support clinic develop
treatment modal patient solid tumor apeiron current develop treatment
advanc solid tumor procedur take less day may compat dc vaccin chimer
antigen receptor car-t tumor infiltr lymphocyt til therapi treatment may also combin
immunotherapi modal antibodi bispecif
figur cbl-b silenc murin cell act model melanoma
safeti profil evalu phase studi patient advanc solid tumor treatment
well toler grade toxic observ mostli transient chill fever
grade toxic occur patient includ fatigu lymphopenia cough dyspnea
pancreat cancer one most-deadli form cancer lead approxim death per year
fourth common caus cancer-rel death us surviv rate
poor prognosi result sever factor includ fact estim new
patient per year us diagnos late stage due lack earli symptom reliabl screen
test symptom includ sever abdomin pain jaundic loss appetit weight loss diarrhea nausea
diagnosi pancreat cancer gener made evalu symptom may includ analysi serum
level often elev pancreat cancer biomark rare detect
molecular pathogenesi pancreat adenocarcinoma well character almost tumor carri
initi mutat kra oncogen mutat predomin c-kit
recent propos enhanc invas pancreat despit strong understand
underli genet correspond advanc target therapeut associ gain
treatment includ surgeri radiat chemotherapi patient elig surgeri
due fact time diagnosi tumor spread beyond pancrea metastat
diseas substanti difficult treat local tumor approv therapeut along target
zhang et al stem cell factor/c-kit signal enhanc invas pancreat cancer cell via
shown figur celgen celg abraxan paclitaxel approv pancreat cancer
base result phase studi show median overal surviv month combin
gemcitabin compar month gemcitabin notabl approv agent chemotherapi
except astella tyo tarceva erlotinib target epiderm growth factor receptor
figur approv pancreat cancer
clinic trial discuss
apeiron complet phase studi use singl administr patient advanc solid
tumor progress diseas preliminari result show evalu patient experienc stabl
diseas pancreat cancer colon cancer addit patient pancreat cancer compassion
use program stabl diseas month base initi sign activ seen
patient pancreat cancer apeiron plan begin phase ii studi patient popul first
half trial plan perform integr custom devic develop miltenyi
privat facilit bedsid treatment notabl sever posit immunomodulatori effect observ
follow treatment increas tumor ifn- product tumor infiltr
lymphocyt til provid rational test treatment combin checkpoint inhibitor
addit checkpoint target sirna compani also current conduct phase ib studi
use multipl infus patient recurr metastat pancreat cancer colorect cancer
solid tumor remov surgeri data readout studi expect first
half
phase studi patient advanc solid tumor diseas
trial design open-label dose-escal phase studi evalu singl dose
patient advanc solid tumor progress treatment consist single-dos
 cbl-b silenc autolog pbmc patient wake forest baptist medic center enrol
von hoff et al increas surviv pancreat cancer nab-paclitaxel plu gemcitabin new england journal
medicin
dose cohort prior enrol patient subsequ higher dose cohort patient observ
least month studi end last patient follow month primari endpoint
trial safeti determin maximum toler dose secondari endpoint includ immunolog
effect overal respons rate measur recist progress free surviv overal surviv os
preliminari trial result first patient experienc stabl diseas sd patient
pancreat cancer colon cancer notabl patient progress late stage diseas time
treatment indic activ residu effect prior treatment addit sinc
therapi consist singl dose multipl dose futur studi could enhanc activ treatment
increas ifn- product observ follow indic immun activ
provid mechanist rational combin approach checkpoint inhibitor ad checkpoint
target sirna pbmc term safeti treatment well toler grade toxic
observ mostli transient chill fever grade toxic occur
patient includ fatigu lymphopenia cough dyspnea
activ observ compassion use program compassion use program open austria
evalu use metastat pancreat cancer patient treat one receiv cycl
treatment per cycl dendrit cell vaccin treatment paus
cycl patient present metastat pancreat cancer lung metastas
administr dendrit cell vaccin cbl-b silenc pbmc administ patient
experienc stabl diseas month atyp see metastat pancreat cancer
refer surviv rate stage diseas increas cell activ pd-
tumor infiltr lymphocyt til follow treatment support combin approach
phase studi patient recurr metastat pancreat cancer colorect cancer
solid tumor remov surgeri
trial design on-going open-label phase ib studi evalu multipl dose patient
recurr metastat pancreat cancer colorect cancer solid tumor remov
patient measur diseas enrol wake forest baptist medic center receiv
period day diseas progress unaccept toxic primari
endpoint safeti secondari endpoint includ overal respons rate measur recist immun
respons measur frequenc immun cell interferon product neutrophil lymphocyt ratio overal
surviv progression-fre surviv apeiron expect report data studi first half
dinutuximab beta intraven iv administ chimer antibodi
gangliosid antigen may receiv market approv eu brand name qarziba
patient month age older high-risk pediatr neuroblastoma rare form cancer compris
roughli childhood tumor approv author except circumst mean post
market surveil use patient registri mandat
apeiron out-licens global right eusa pharma privat septemb term
agreement apeiron receiv undisclos up-front payment elig regulatori mileston
payment follow market author select territori royalti product sale apeiron
expect bla submit fda eusa second quarter clinic studi also
perform japan support approv territori grant track design
fda orphan drug design us eu given target condit primarili affect pediatr
patient potenti receiv pediatr diseas prioriti review voucher fda
approv voucher sold compani price typic surpass million reach
mechan action mouse-human chimer monoclon antibodi produc
chines hamster ovari cho cell commonli use host cell make therapeut protein bind
cell express induc antibodi depend cell-medi cytotox adcc complement
depend cytotox cdc presenc effector cell and/or complement protein shown
abil mediat lysi human neuroblastoma cell line dose-depend manner
gangliosid antigen background disialogangliosid antigen ubiquit found
surfac tumor cell neuroectodern origin addit tumor type
express includ rare pediatr malign osteosarcoma soft tissu sarcoma ewe sarcoma
well adult malign like small cell lung cancer sclc melanoma glioblastoma breast cancer provid
futur potenti develop opportun notabl resist antibodi rare result antigen
normal tissu express mostli limit neuron skin melanocyt peripher pain fiber
make feasibl antigen target
neuroblastoma third common childhood cancer behind leukemia brain tumor
common solid extra-crani tumor children approxim new case us year
also primari caus cancer-rel death pediatr patient diseas character
myriad symptom depend primari tumor aris spread whether secret
hormon diseas often asymptomat earli stage result patient
present advanc metastat diseas requir treatment current standard care neuroblastoma
involv observ case multimod immunotherapi chemotherapi radiotherapi surgeri
other despit number therapi avail treat neuroblastoma high-risk patient
aliv year diagnosi highlight need addit therapi receiv eu approv may
patient month age older high-risk neuroblastoma notabl immunotherapi
approv eu diseas
yang sondel strategi treatment neuroblastoma drug futur
kramer et al disialogangliosid loss follow monoclon antibodi therapi rare neuroblastoma
svennerholm et al gangliosid alli glycosphingolipid human peripher nerv spinal cord biochimica
 et al neuroblastoma incid surviv european children report autom
childhood cancer inform system project european journal cancer
caus pathogenesi neuroblastoma development tumor sympatho-adren lineag
neural crest specif within neuron ganglia structur sympathet nervou system neural crest
transient embryolog tissu undergo uniqu matur process neural crest precursor gain
multipot differenti potenti thu self-renew phenotyp similar embryon stem cell
matur direct complex transcript factor epigenet regulatori schema ultim signal
cascad activ variou ligand involv embryogenesi stimul matur multipot neural crest cell
differenti compon face trunk heart includ peripher sympathet ganglia
differ transcript factor involv stage neural crest matur process inappropri
activ transcript factor may predispos earli multipot precursor malign transform
exampl express pro-surviv factor foxd c-myc mycn result highli
prolif cell resist apoptosi well understood disrupt matur result
neuroblastoma oncogenesi singl genet epigenet mutat determin multipl gene
implic across differ classif neuroblastoma addit copi mycn gene
promot cellular prolifer block tumor suppressor gene seen case
neuroblastoma activ mutat anaplast lymphoma kinas gene link sympathet
neuron develop surviv migratori neural crest cell seen nearli case famili neuroblastoma
spontan neuroblastoma case paired-lik homeobox gene normal
drive differenti neural crest precursor toward sympathet neuron mutat gene contribut
specif subset neuroblastoma tumor mutat epigenet factor non-cod rna also
implic diseas develop
ultim mutat prevent matur neural precursor cell matur nerv cell lead
format malign solid tumor specif nerv tissu neuroblastoma may aris adren
medulla abdomin paraspin ganglia account neuroblastoma tumor
respect remain tumor may deriv sympathet ganglia chest head/neck
pelvi given number oncogen driver diseas signific molecular heterogen associ
neuroblastoma manifest signific clinic heterogen diseas present progress
symptom due number site neuroblastoma may aris present symptom vari wide
among patient furthermor sign symptom diseas differ depend whether tumor secret
hormon diseas spread earli stage diseas gener asymptomat
patient present advanc stage diseas one common sign presenc
abdomin mass child accompani abdomin pain decreas appetit weight loss
neuroblastoma tumor aris neck patient often report presenc hard painless lump may caus
difficulti breath swallow tumor aris chest may also caus mass effect similar
seen abdomen compress superior vena cava result swell face neck arm upper
chest may also caus dizzi headach chang conscious
neuroblastoma may also result metastasi paraneoplast syndrom due secret catecholamin
includ norepinephrin epinephrin approxim two-third tumor metastas lymph
loui md mph cu et al neuroblastoma molecular pathogenesi therapi annu pp
node distant site time diagnosi made bone metastasi often present bone pain caus
difficulti walk spread bone spine patient may experi weak numb
paralysi arm leg spinal cord compress paraneoplast syndrom may result releas
hormon cell within tumor releas catecholamin hormon typic releas
cell adren medulla result fever diarrhea elev heart rate blood pressur flush sweat
diagnosi stage diagnosi neuroblastoma begin care analysi clinic present
includ medic histori physic exam laboratori assess secret catecholamin tumor cell
common caus increas level norepinephrin epinephrin circul metabol
compound result increas circul level homovanil acid hva vanillylmandel acid vma
assess patient blood sampl imag done determin locat tumor
ultrasound x-ray often first imag modal use comput tomographi ct imag magnet
reson imag mri positron emiss tomographi pet scan bone scan symptom suggest
bone metastasi may also util diagnost process tumor locat determin
biopsi collect confirm diagnosi neuroblastoma depend locat tumor biopsi
may done surgic less invas techniqu use needl ct ultrasound machin guid
patient diagnos neuroblastoma diseas stage order determin appropri treatment
intern neuroblastoma stage inss develop modifi base
resect patholog featur tumor figur list criteria stage use inss
tumor may spontan regress differenti benign ganglioneuroma diseas may follow
unrel progress cours result mortal case tumor expect spontan
regress inss use
local tumor complet gross resect region lymph node involv
local tumor incomplet gross resect ipsilater lymph node involv
tumor cross midlin tumor contralater lymph node involv
patient younger month local tumor metastasi confin liver skin
tumor distant metastasi
anoth stage system known intern neuroblastoma risk group stage ingrss
develop focus imag rather surgic patholog featur design
mccarvil mb imag neuroblastoma radiologist need know cancer imag
use parallel inss ingrss classifi diseas stage base presenc one
defin imaging-defin risk factor idrf tumor local tumor involv
vital structur confin one bodi caviti tumor local region tumor one idrf
may continu across two bodi caviti stage defin metastat diseas includ non-region
distant lymph node metastasi idrf predict risk tumor resect base tumor locat rel
neighbor structur includ blood vessel organ nerv plexus respiratori airway tumor may encas
infiltr compress structur resect tumor may result impair function said vital
structur case tumor safe
treatment treatment recommend patient neuroblastoma base patient mortal risk
result cure rate greater children treatment rang observ aggress
multimod immunotherapi chemotherapi patient local tumor gener consid non-high
risk patient event free surviv rate measur often taken limit amount
therapi administ exampl patient less month age small tumor local
adren gland standard care observ studi patient popul well outcom data
patient less month local similarli size tumor led observ becom
wide accept treatment approach patient also form basi propos within
children oncolog group evalu use observ broader age rang neuroblastoma
patient similar clinic pictur asymptomat infant inss diseas also observ
non-high-risk patient local tumor recommend depend presenc imag defin risk
factor idrf complet tumor excis prefer treatment approach patient tumor
neoadjuv chemotherapi prior tumor excis may attempt patient
high-risk patient receiv multimod treatment involv chemotherapi surgeri radiotherapi biolog
immunotherapi chemotherapi agent commonli use includ carboplatin cyclophosphamid doxorubicin
etoposid vincristin often use combin one anoth high risk patient
higher dose greater number agent may includ within treatment immunotherapi agent
unit corpor unituxin dinutuximab antibodi
approv us combin granulocyte-macrophag colony-stimul factor gm-csf
shown largest impact event-fre overal surviv children whose diseas
progress prior receiv immunotherapi phase studi random patient receiv cis-
retino acid alon cis-retino acid combin gm-csf unituxin result show use
immunotherapi led event free surviv overal surviv compar event-fre
overal surviv rate respect non-immunotherapi group result form
basi immunotherapi becom key compon treatment regimen
although effect unituxin black box warn life-threaten infus reaction sever
neuropath pain associ target addit sever peripher sensori neuropathi rang
neuroblastoma patient receiv treatment immunotherapi approv
eu us file expect second quarter notabl due lack alpha-g glycosyl
shown less allergen unituxin also use combin gm-csf
thu avoid side effect cytokin furthermor due longer infus time continu
mccarvil mb imag neuroblastoma radiologist need know cancer imag
induc less neuropath pain unituxin provid toler potenti desir
oncologist current investig correl biomark better understand patient like
respond standard treatment develop refractori diseas overal surviv rate children
neuroblastoma vari base risk group defin track surviv time
diagnosi patient classifi low intermedi high risk depend tumor stage
patient age diagnosi genet compon diseas presenc metastasi children low-risk group
surviv rate greater intermediate-risk group surviv rate
five-year surviv significantli lower high-risk group estim
despit multimod treatment although patient lower risk diseas requir
intens therapi success treat diseas low surviv rate high-risk patient clearli indic need
treatment improv patient outcom
epidemiolog neuroblastoma common-extra cranial solid tumor childhood account
cancer children us incid estim new case per year
us though may underestim neuroblastoma tumor regress infant medic
attent eu estim children effect diseas median
age diagnosi approxim month case diagnos age neuroblastoma
report ethnic group us incid rate case per children age
white black asian/pacif island american indian/alaskan nativ hispan ethnic group
respect neuroblastoma primari caus death pediatr cancer children
account pediatr cancer estim patient low-risk diseas
intermedi risk remain high risk diseas notabl patient high-risk
neuroblastoma relaps follow initi treatment
clinic trial discuss
approv eu primarili base follow three clinic studi
studi retrospect analysi compassion use program use singl
center patient includ heterogen popul r/r neuroblastoma
studi random control phase studi compar ra
phase i/ii trial evalu plu patient r/r neuroblastoma
loui md mph cu et al neuroblastoma molecular pathogenesi therapi annu
 et al neuroblastoma incid surviv european children report autom
childhood cancer inform system project european journal cancer
result trial show favor event free surviv overal surviv rate compar match
histor control receiv market author except circumst mean post
market surveil use patient registri mandat figur highlight key find list
studi form basi ema approv addit describ result phase trial
use data present american societi clinic oncolog confer
figur activ r/r neuroblastoma data cut-off
strength evid
limit inform
limit inform
imbal
phase studi compar without follow first line therapi
phase studi evalu use isotretinoin without therapi
front-lin treatment children high-risk neuroblastoma overal ef os result compar
favor histor control patient popul addit use treatment regimen
lead improv surviv toxic profil increas toxic suggest
ladenstein et al toxic outcom antibodi front-lin high risk neuroblastoma
patient final result phase immunotherapi random trial
administ alon would result toler treatment use associ infect
pancytopenia capillari leak syndrom aggrav auto-immun diseas renal and/or hepat impair
trial design open-label random phase studi enrol patient first-lin high-risk
random patient receiv either day daili
short term infus alon sti-a combin day
cycl cycl sti-b patient also receiv cycl given oral day
pretreat high intens induct follow autolog stem cell transplant local therapi
primari endpoint trial event free surviv year
trial result event free surviv ef overal surviv os patient treat sti-a
patient treat sti-b ef os statist
signific shown figur ef patient complet respons good
partial respons vgpr partial respons pr also show statist signific differ
two group note lanski perform statu compris sti-a patient versu
sti-b patient suggest slight enrol bia favor sti-a group lanski perform
statu classif system higher statu percentag correl better prognosi term safeti earli
treatment termin due toxic higher sti-b arm sti-a arm grade
toxic capillari leak syndrom vs common terminolog criteria ctc -fever
ctc-allerg reaction vs also favor sti-a arm
figur result /-
ef patient
os patient
contain sever advantag unituxin due lack alpha-g glycosyl
shown less allergen unituxin also use combin gm-csf thu avoid
cost side effect cytokin infect pancytopenia capillari leak syndrom aggrav
auto-immun diseas renal and/or hepat impair neuropath pain observ anti-
antibodi patient often requir co-administr analges drug morphin toler
treatment dose target antibodi typic short-term
infus sti hour subsequ day correl observ infus time
toxic prompt apeiron develop use slower infus time given
continu long-term infus lti compar publish research use sti infus lti result lower
frequenc neuropath pain vs seriou treatment emerg advers event teae also
occur lower frequenc includ could lead reduc use analges care need
anaphylact reaction seen target antibodi
fulli human monoclon antibodi genet fuse human apeiron in-
licens asset merck kgaa proof-of-concept agent establish phase
ii studi relapsed/refractori neuroblastoma overal respons rate treatment around
patient low tumor burden melanoma monotherapi evalu phase ii studi patient
late stage diseas one patient experienc partial respons stabl diseas short half-lif
potenti limit activ intraven treatment base result preclin studi
use intratumor treatment investigator-sponsor phase studi evalu intratumor
melanoma plan begin first half initi data come apeiron also intend
initi clinic studi pediatr cancer use intratumor second half
mechan action consist fulli human monoclon mab antibodi
genet fuse human target mab portion treatment bind tumor
cell follow recruit natur killer nk cell tumor site via fuse
recruit immun cell allow better recogn cancer specif antigen lead immun
mediat cell death addit sinc antibodi also mediat cell death via antibody-
depend cellular cytotox adcc complement-depend cytotox cdc
preclin studi intratumor
evalu sever preclin model demonstr anti-tumor activ experi
describ demonstr abil addit effect radiat /- therapi
melanoma mous model tumor growth inhibit greater degre mice receiv tripl combin
compar two-drug treatment regimen coincid greatest surviv time apeiron intend
evalu tripl combin approach futur clinic studi
mueller et al toler respons outcom high-risk neuroblastoma patient treat long-term infus
antibodi mab
show synergist effect radiat therapi effect combin
intratumor radiat therapi evalu syngen
melanoma mous model figur depict result mice xenograft melanoma
cell treatment began tumor volum reach approxim larger volum
preclin oncolog studi difficult treat mice receiv singl fraction radiat gy sham
radiat day daili intratumor inject control igg day intraperiton
ip inject control igg day
depict monotherapi small effect tumor volum growth inhibit surviv
compar igg control antibodi howev combin radiat gy radiat
therapi synergist effect lead improv tumor growth inhibit top panel surviv bottom
panel versu mice treat two-drug combin monotherapi chang statist signific
indic key group overal complet tumor regress observ
mice receiv tripl combin compar mice receiv radiat
mice receiv radiat therapi mice receiv
treatment regimen notabl mice experienc complet respons nearli reject
secondari tumor upon rechalleng suggest adapt immun develop
figur antitumor activ radiat /- therapi
observ treatment effect could due follow immun mechan
radiat deplet immunosuppress regulatori cell treg increas antigen present
antigen present cell apc result improv cell recognit tumor evid
preclin experi treatment radiat led increas tumor infiltr nk cell
follow antibodi bind posit cell nk cell attract tumor cell
induc cell death via adcc increas antigen present apc addit
conjug abl activ cell direct tumor microenviron via
apc taken tumor specif antigen radiat kill cancer cell preclin
experi show treatment led increas tumor infiltr nk cell
cell increas combin radiat modest increas ifn- note
treatment lead signific increas cell
even immun recognit respons cancer associ antigen immun
checkpoint prevent recognit kill tumor cell immun cell
use antibodi checkpoint prevent inhibit immun respons allow
anti-tumor immun respons take place
safeti profil phase ii studi evalu intraven neuroblastoma treatment toler
advers event resolv within day treatment patient enrol discontinu
treatment due treatment relat advers event grade although patient experi
grade toxic common includ platelet reduct lymphocyt reduct
alt elev ast elev bilirubin elev note administr typic
result toler safeti profil oncolog treatment demonstr therapi
melanoma cancer pigment-produc skin cell known melanocyt gener caus
combin genet risk factor ultraviolet light exposur sun estim new case
melanoma diagnos us patient die diseas addit
diagnos expect eu melanoma make total cancer diagnos account
roughli skin cancer although nearli peopl diseas cure identifi earli
surviv patient grade melanoma patient grade iv diseas grade
iv melanoma make roughli case diseas us non-hispan white male
histor highest risk melanoma follow non-hispan white femal sun exposur light skin
pigment contribut significantli develop melanoma howev melanoma possibl
type skin area bodi typic receiv sun
shusterman et al antitumor activ patient relapsed/refractori neuroblastoma
children oncolog group phase ii studi journal clinic oncolog
siegel et al cancer statist ca cancer journal clinician
ncnn clinic practic guidelin oncolog melanoma
type melanoma four type melanoma differ somewhat physic featur although
gener carri level health risk melanoma categori outlin figur three
type superfici spread lentigo maligna acral lentigin begin situ lesion mean
occupi superfici layer skin later progress invas state nodular melanoma usual
invas time diagnosi aggress form melanoma major melanoma
highli treatabl difficult identifi still situ state overal surviv patient
melanoma
figur type melanoma
repres case
spread along epidermi period month year
penetr deeper
flat bare rais lesion often irregular border
aris lentigo small pigment spot
take mani year develop
often chronic sun-expos area
tend occur palm sole nail
common melanoma peopl african asian
repres melanoma
usual invas time diagnosi
aggress melanoma
caus pathogenesi melanoma cancer result abnorm growth transform
melanocyt skin one three type skin cancer carri substanti higher risk morbid
mortal form type skin cancer squamou cell carcinoma origin cell
middl epiderm layer basal cell carcinoma begin cell basal layer epidermi skin
cancer primarili caus cumul exposur ultraviolet radiat cours individu lifetim
factor contribut develop skin cancer tobacco smoke immunosuppress
medic genet syndrom congenit melanocyt nevi syndrom
certain gene commonli mutat melanoma may specif tie pathogenesi figur
display estim preval gene mutat commonli mutat gene
sullivan fisher understand biolog melanoma therapeut implic hematolog
melanoma found case braf encod intracellular protein protein part
broader signal transduct pathway map kinas mapk pathway often alter melanoma
figur estim oncogen mutat rate melanoma
treatment initi treatment melanoma gener involv excis malign tissu sinc type
cancer aggress invad surround tissu extent tissu excis depend stage
cancer found surgeon perform excis tri remov cancer tissu minim
damag surround healthi tissu gener involv level guesswork due need
ensur cancer cell remain boundari set surgeon tend aggress
stage melanoma near cure rate due well surgeri remov full lesion advanc
melanoma difficult treat usual requir substanti amount tissu remov ensur full
extent cancer tissu excis melanoma spread inoper system immunotherapi like
bristol-my squibb yervoy ipilimumab opdivo nivolumab often use agent also carri
substanti cost around year treatment combin checkpoint inhibitor becom
backbon mani cancer treatment futur treatment often consist combin
therapeut opdivo also indic use adjuv therapi patient complet resect
melanoma lymph node involv metastat diseas
case patient progress respond inhibitor agent yervoy target therapi
specif cancer-caus mutat chemotherapi drug clinic trial recommend roughli half
melanoma mutat braf gene patient mutat either prescrib braf inhibitor
first-lin treatment follow progress checkpoint inhibitor novarti nyse nv tafinlar
dabrafenib roch vtx rog vx zelboraf vemurafenib braf inhibitor approv
treatment melanoma often combin mek inhibitor mekinist trametinib cotel
cobimetinib due increas efficaci
epidemiolog american cancer societi estim peopl us diagnos
melanoma die diseas addit estim case diagnos
annual approxim melanoma patient diagnos stage iv diseas
often prescrib inhibitor treatment surviv rate patient stage
melanoma patient grade iv diseas expect surviv rate improv follow
rel recent approv keytruda opdivo yervoy current evalu patient
advanc melanoma figur outlin treatment group advanc diseas assumpt
follow
stage iv melanoma checkpoint inhibitor consid standard care roughli
melanoma patient present stage iv diseas
treat inhibitor base discuss physician focus treatment
melanoma believ around three-fourth patient stage iii/iv diseas receiv
inhibitor frontlin treatment
fail treatment melanoma patient respond frontlin pd-
figur potenti patient popul
incid melanoma
patient stage iii/iv diseas
patient respond inhibitor
larkin et al combin nivolumab ipilimumab monotherapi untreat melanoma new england journal
medicin
carolin et al pembrolizumab versu ipilimumab advanc melanoma new england journal medicin
daud et al tumor immun profil predict respons therapi human melanoma journal
clinic trial discuss
iv evalu monotherapi phase ii studi patient relapsed/refractori
neuroblastoma phase ii studi patient late stage melanoma neuroblastoma trial
demonstr proof concept evalu patient one studi experienc overal respons rate
orr respons complet note respond patient
low diseas burden second studi combin agent gm-csf r/r neuroblastoma similar
respons rate observ patient low diseas burden activ low diseas burden patient
consist preclin data show improv activ smaller tumor suggest iv deliveri
drug may best util patient minim residu diseas current test
investigator-l phase ii studi patient resect recurr stage stage iv melanoma
complet phase ii advanc melanoma studi one patient experienc partial respons
stabl diseas notabl iv short half-lif around hour potenti limit applic
iv treatment base preclin result use intratumor therapi investigator-l phase studi
evalu intratumor melanoma expect begin first half initi data
come apeiron also intend initi clinic studi pediatr malign
neuroblastoma second half base preclin result compani may also
conduct studi combin radiat antibodi
phase ii studi iv advanc melanoma
trial design open-label single-sit phase ii studi evalu patient measur
metastat trial two-stag design patient plan enrol univers
wisconsin hospit clinic receiv iv day
treatment cycl continu infus respons observ first patient
studi would close due lack efficaci respons seen least patient addit
patient could enrol patient experienc stabl diseas sd tumor regress follow cycl could
receiv addit treatment cycl primari object studi evalu anti-tumor activ
respons durat secondari object includ safeti immunolog activ
trial result first patient enrol partial respons pr treatment sd allow
receiv total cycl treatment pr sd respons last month
progress one pr met criteria need progress stage studi suspend part due
brief durat respons importantli immun activ observ treat patient evidenc
rebound lymphocytosi increas level elev crp adcc bode well potenti
combin approach checkpoint inhibitor sinc activ depend patient immun
respons cancer term safeti observ toxic revers follow cessat
treatment advers event led dose reduct includ grade hypotens patient grade
shusterman et al antitumor activ patient relapsed/refractori neuroblastoma
children oncolog group phase ii studi journal clinic oncolog
albertini et al phase ii trial patient metastat melanoma cancer immunolog
renal insuffici oliguria patient three patient dose reduct abl receiv
subsequ dose patient experienc grade lymphopenia grade sever common grade
includ hypophosphatemia thrombocytopenia hyperglycemia
investig sponsor studi iv resect recurr melanoma
trial design open-label random phase ii studi evalu patient resect
recurr stage iv patient random univers wisconsin hospit
clinic receiv one two follow regimen
iv day cycl follow surgeri addit
cycl
surgeri follow cours iv given day cycl
primari endpoint studi diseas evalu ct scan occur everi month
month everi month
follow initi approv checkpoint inhibitor field immunotherapi drug develop quickli
grown combin studi inhibitor on-going approv
immunotherapi combin treatment involv therapi melanoma
chemotherapi therapi lung cancer one popul focu immunotherapi candid patient
progress checkpoint inhibitor sever treatment develop popul shown
encourag sign activ earli clinic studi list figur note
therapi also develop earlier line treatment
figur select treatment develop patient progress inhibitor
mechan
phase
iv
approv
small-molecul checkpoint inhibitor undisclos novel target preclin develop
solid tumor hematolog cancer checkpoint inhibitor bristol-my squibb nyse opdivo
becom import treatment option cancer new checkpoint target highli sought larg
biotech pharma notabl current avail checkpoint inhibitor antibodi administ
intraven depend activ safeti profil apeiron oral administ small-molecul may offer
conveni toler profil patient august announc compani
enter strateg collabor evotec evt sanofi nyse sni develop novel small-
molecul checkpoint inhibitor includ term agreement sanofi fund
year research apeiron evotec compani opportun receiv
million million combin pre-clin clinic regulatori commerci mileston addit royalti
net sale commerci
lead candid discov use primari ht assay done evotec human peripher
blood mononuclear cell pbmc use compound goal assay identifi compound
primarili enhanc cytokin product activ primari human cell compani progress
seri sanofi may advanc clinic apeiron also evalu preclin
studi base differ substanc class target fulli own compani
addit peptid approach target cbl-b earli preclin develop in-licens
institut molecular biotechnolog vienna
figur show preclin result one earli candid seri call
depict treatment human cell cpd lead increas ifn- product
compar yervoy ipilimumab celgen celg revlimid lenalidomad dmso control
current market checkpoint inhibitor cpi monoclon antibodi
oral avail compound offer potenti easier administr better side
preclin pipelin partnership
collabor evotec
sanofi identifi novel oral avail
apeiron receiv mileston
futur royalti sanofi
checkpoint inhibitor earli preclin
figur immunolog effect
cytokin product administr
compound concentr g/ml
compound concentr g/ml
recombin form human angiotensin convert enzym complet phase ii
studi acut lung injuri ali acut respiratori distress syndrom ard fund glaxosmithklin
nyse outlicens glaxosmithklin follow phase studi term
licens deal apeiron elig receiv million million total mileston payment plu
royalti net product sale commerci compani receiv up-front payment
million million million million mileston payment occur follow start phase ii
recent inform apeiron disclos revenu total million million
primarili eusa pharma partner compani disclos expect regular
revenu flow sourc compani receiv clearanc million million eib
loan yet util septemb compani cash cash equival
million million expect fund oper
apeiron number us intern patent grant and/or pend surround product portfolio
development platform patent surround expir pertain
expir composit matter pend patent applic
europ grant expir patent pertain expir
dr loibner receiv phd organ chemistri univers vienna year
research develop manag experi includ sandoz/novarti dr loibner found
develop biotechnolog compani igeneon develop cancer immunotherapi treatment
chief offic chief busi offic
mr llewellyn-davi year experi healthcar financ activ intern
deal compani turnaround licens transact previous cfo/cbo medigen ag cfo
wilex ag sit multipl board includ shield therapeut apeiron mr llewellyn-davi main
respons includ financ busi develop corpor commun legal affair
dr westritschnig receiv md univers vienna special immunolog dr
westritschnig year experi academia industri work sanochemia
vice presid clinic develop intercel valneva join apeiron
risk invest
consid invest apeiron high-risk invest apeiron current clinical-stag
develop wholli own market approv product compani enter
phase clinic trial current clinic program failur show convinc result futur pivot clinic
studi failur reach fda ema approv could neg affect compani valuat abil
rais capit regulatori approv market sell drug guarante drug penetr
market sale may meet expect clinical-stag compani apeiron profit may need
seek addit financ may result dilut exist sharehold valu
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
